Showing results (621-630 of 1,892) with videos related to
Sort By:
Pageof 190
Immunotherapy|February 26, 2015
Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of grayNicky J C Woittiez, Bart O RoepImmunotherapy|May 4, 2023
Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysisHui Liu, Chun-Cheng Yang, Yun-Long Ma, et al.Immunotherapy|April 4, 2023
Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer centerRebecca Jeun, Priyanka C Iyer, Conor Best, et al.Immunotherapy|May 17, 2023
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseasesDavid J Jackson, Praveen Akuthota, Rebeca Andradas, et al.Immunotherapy|May 17, 2023
Upadacitinib for moderate to severe atopic dermatitisFrancisco Navarro-Triviño, Sara Alcantara-Luna, Javier Domínguez-Cruz, et al.Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.Immunotherapy|May 16, 2023
Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanomaCynthia Yeung, Adi Kartolo, Justin Tong, et al.Immunotherapy|July 9, 2020
Adoptive Treg cell-based immunotherapy: Frontier therapeutic aspects in rheumatoid arthritisMahdi Zavvar, Sara Assadiasl, Sina Zargaran, et al.Immunotherapy|July 24, 2020
Neem leaf glycoprotein reverses tumor-induced and age-associated thymic involution to maintain peripheral CD8+ T cell poolIpsita Guha, Avishek Bhuniya, Partha Nandi, et al.Immunotherapy|July 3, 2020
Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case reportFei Xu, Jing Zheng, Mengjiao Fu, et al.Pageof 190